Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660013 | 0.80 | NPC1 (0.47) | HRH3HRH4HRH2HRH1TDP1 | |
| SCHEMBL6681517 | 0.78 | HRH3 (0.46) | HRH3HRH4HRH2HRH1TDP1 | |
| SCHEMBL6736067 | 0.78 | HRH3 (0.46) | HRH3HRH4HRH2HRH1TDP1 | |
| SCHEMBL11041850 | 0.72 | HRH4 (0.60) | HRH3HRH4HRH2HRH1TDP1 | |
| SCHEMBL24023138 | 0.70 | HRH3 (0.58) | HRH3HRH4HRH2HRH1TDP1 | |
| SCHEMBL14131260 | 0.69 | — | — | |
| SCHEMBL10741491 | 0.68 | HRH2 (0.55) | HRH3HRH4HRH2HRH1TDP1 | |
| SCHEMBL5157359 | 0.68 | GABRR1 (0.56) | HRH3HRH4HRH2HRH1TDP1 | |
| SCHEMBL1490164 | 0.67 | KCNA3 (1.00) | KCNA3HTR1BLTA4HALDH1A1 | |
| SCHEMBL1025 | 0.67 | KCNA3 (0.88) | KCNA3HTR1BLTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446385-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2004-08-18 | — | — | EP | disclosed |
| US-20040127718-A1 | Substituted imidazoles | NOVO NORDISK A/S (DK) | 2004-07-01 | — | — | US | disclosed |
| US-20030181479-A1 | Substituted imidazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| WO-2003040106-A1 | PREPARATION AND USE OF SUBSTITUTED IMIDAZOLES | NOVO NORDISK A/S (DK) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181479-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | HRH3 1/4885HRH4 2/4885HRH2 3/4885 |
| US-20040127718-A1 | Substituted imidazoles | HRH3, HRH4, HRH2 | HRH3 1/4885HRH4 2/4885HRH2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.